NO20091265L - Pyrrolopyrazin som Syk-kinase inhibitor - Google Patents

Pyrrolopyrazin som Syk-kinase inhibitor

Info

Publication number
NO20091265L
NO20091265L NO20091265A NO20091265A NO20091265L NO 20091265 L NO20091265 L NO 20091265L NO 20091265 A NO20091265 A NO 20091265A NO 20091265 A NO20091265 A NO 20091265A NO 20091265 L NO20091265 L NO 20091265L
Authority
NO
Norway
Prior art keywords
pyrrolopyrazine
kinase inhibitor
syk kinase
compound
prodrugs
Prior art date
Application number
NO20091265A
Other languages
English (en)
Norwegian (no)
Inventor
Timothy A Gillespy
Paul Eynott
Elizabeth M Allen
Kin T Yu
Asher Zilberstein
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20091265L publication Critical patent/NO20091265L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20091265A 2006-09-11 2009-03-26 Pyrrolopyrazin som Syk-kinase inhibitor NO20091265L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82516806P 2006-09-11 2006-09-11
PCT/US2007/078103 WO2008033798A2 (en) 2006-09-11 2007-09-11 A pyrrolopyrazin as syk-kinase inhibitor

Publications (1)

Publication Number Publication Date
NO20091265L true NO20091265L (no) 2009-04-03

Family

ID=39032357

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091265A NO20091265L (no) 2006-09-11 2009-03-26 Pyrrolopyrazin som Syk-kinase inhibitor

Country Status (32)

Country Link
US (2) US8658649B2 (enExample)
EP (1) EP2094708B1 (enExample)
JP (1) JP5161237B2 (enExample)
KR (1) KR101443056B1 (enExample)
CN (2) CN103804383A (enExample)
AR (1) AR062745A1 (enExample)
AU (1) AU2007296592B8 (enExample)
BR (1) BRPI0716781A2 (enExample)
CA (1) CA2663175C (enExample)
CL (1) CL2007002617A1 (enExample)
CO (1) CO6160236A2 (enExample)
CR (1) CR10636A (enExample)
DK (1) DK2094708T3 (enExample)
ES (1) ES2437318T3 (enExample)
GT (1) GT200900055A (enExample)
HN (1) HN2009000455A (enExample)
IL (1) IL197381A (enExample)
MA (1) MA30781B1 (enExample)
MX (1) MX2009002616A (enExample)
MY (1) MY148107A (enExample)
NI (1) NI200900021A (enExample)
NO (1) NO20091265L (enExample)
NZ (1) NZ575496A (enExample)
PE (1) PE20081372A1 (enExample)
PT (1) PT2094708E (enExample)
RU (1) RU2440352C2 (enExample)
TN (2) TN2009000049A1 (enExample)
TW (1) TWI399379B (enExample)
UA (1) UA94622C2 (enExample)
UY (1) UY30584A1 (enExample)
WO (1) WO2008033798A2 (enExample)
ZA (1) ZA200901073B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2247595B1 (en) 2008-02-25 2011-07-20 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
RU2503676C2 (ru) 2008-02-25 2014-01-10 Ф.Хоффманн-Ля Рош Аг Пирролопиразиновые ингибиторы киназы
DK2250172T3 (da) 2008-02-25 2012-01-16 Hoffmann La Roche Pyrrolopyrazinkinaseinhibitorer
ATE519763T1 (de) 2008-02-25 2011-08-15 Hoffmann La Roche Pyrrolopyrazin-kinasehemmer
ES2372908T3 (es) * 2008-02-25 2012-01-27 F. Hoffmann-La Roche Ag Inhibidores de la pirrolopirazina quinasa.
NZ587906A (en) * 2008-03-10 2011-12-22 Sanofi Aventis Treatment for ocular-related disorders
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
PA8851701A1 (es) 2008-12-03 2010-07-27 Sanofi Aventis Tratamiento para la glomerulonefritis
TW201033211A (en) 2008-12-04 2010-09-16 Sanofi Aventis Crystalline forms
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
US20110112101A1 (en) * 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders
AR075869A1 (es) * 2009-03-19 2011-05-04 Sanofi Aventis Sintesis de azaindoles
SG181857A1 (en) 2009-12-23 2012-07-30 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
US8481541B2 (en) 2010-03-22 2013-07-09 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8518945B2 (en) 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
CA2799904A1 (en) * 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors
CA2798970A1 (en) 2010-05-20 2011-11-24 F. Hoffmann-La Roche Ag Pyrrolopyrazine derivatives as syk and jak inhibitors
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
KR20150043323A (ko) * 2012-08-21 2015-04-22 에프. 호프만-라 로슈 아게 비장 티로신 키나제 억제제로서 피롤로[2,3-b]피라진
AU2014296184B2 (en) 2013-07-31 2017-04-27 Gilead Sciences, Inc. Syk inhibitors
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116969927B (zh) * 2023-06-07 2024-03-19 中南民族大学 一种从荜茇中提取分离的化合物及该化合物在制备抗炎药物中的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1141949A (en) 1966-02-23 1969-02-05 Sterling Drug Inc 7-azaindole derivatives
US3992392A (en) 1973-04-27 1976-11-16 The Ohio State University Research Foundation Synthesis of indoles from anilines and intermediates therein
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
FR2732969B1 (fr) 1995-04-14 1997-05-16 Adir Nouveaux composes pyridiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE69728688T2 (de) 1996-11-19 2004-08-19 Amgen Inc., Thousand Oaks Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel
US6312835B1 (en) 1997-02-13 2001-11-06 Queen's University At Kingston Luminescent compounds and methods of making and using same
ATE242245T1 (de) 1997-03-19 2003-06-15 Basf Ag Pyrrolo(2,3-d)pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
AU7132998A (en) 1997-04-24 1998-11-13 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
ID24300A (id) 1997-08-05 2000-07-13 Pfizer Prod Inc 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y
AU745579B2 (en) 1997-10-20 2002-03-21 F. Hoffmann-La Roche Ag Bicyclic kinase inhibitors
AU767599B2 (en) 1998-03-06 2003-11-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
JP2002510685A (ja) 1998-04-02 2002-04-09 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬
AU3210799A (en) 1998-04-02 1999-10-25 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6673797B1 (en) 1998-05-26 2004-01-06 Chugai Seiyaku Kabushiki Kaisha Heterocyclic indole derivatives and mono- or diazaindole derivatives
CN1326457A (zh) 1998-09-18 2001-12-12 巴斯福股份公司 作为激酶抑制剂的4－氨基吡咯并嘧啶
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
WO2001047922A2 (en) 1999-12-24 2001-07-05 Aventis Pharma Limited Azaindoles
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
YU54202A (sh) 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
DE10009000A1 (de) 2000-02-25 2001-08-30 Basf Ag Verfahren zur Herstellung substituierter Indole
CA2402516A1 (en) 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
WO2001082930A1 (en) 2000-05-03 2001-11-08 Tularik Inc. Pyrazole antimicrobial agents
US6943174B2 (en) 2000-06-14 2005-09-13 Warner-Lambert Company 6,5-Fused bicyclic heterocycles
AU2002211828A1 (en) 2000-10-02 2002-04-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
WO2003000690A1 (en) 2001-06-25 2003-01-03 Aventis Pharmaceuticals Inc. Synthesis of heterocyclic compounds employing microwave technology
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP1441725A1 (en) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
US20040082365A1 (en) * 2002-07-18 2004-04-29 Celerica Ltd Digitization and transmitting cellular RF signals by several light wavelengths
EP1388541A1 (en) 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines as kinase inhibitors
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
EP1778687A2 (en) * 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876582B1 (fr) 2004-10-15 2007-01-05 Centre Nat Rech Scient Cnrse Utilisation de derives de pyrrolo-pyrazines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules
BRPI0517652A (pt) 2004-11-08 2008-10-14 Baxter Healthcare Sa composições farmacêuticas nanoparticuladas de inibidores de tubulina, métodos para as suas preparações e respectivos usos
US20060122185A1 (en) * 2004-11-22 2006-06-08 Jeremy Green Bicyclic inhibitors of Rho kinase
US20110112101A1 (en) 2009-03-05 2011-05-12 Sanofi-Aventis Treatment for ocular-related disorders

Also Published As

Publication number Publication date
BRPI0716781A2 (pt) 2014-11-18
NI200900021A (es) 2010-01-29
MA30781B1 (fr) 2009-10-01
KR101443056B1 (ko) 2014-09-22
NZ575496A (en) 2011-09-30
AU2007296592B8 (en) 2012-01-12
KR20090063214A (ko) 2009-06-17
TW200829590A (en) 2008-07-16
HN2009000455A (es) 2012-02-13
JP2010502767A (ja) 2010-01-28
MX2009002616A (es) 2009-03-24
AR062745A1 (es) 2008-12-03
EP2094708A2 (en) 2009-09-02
ES2437318T3 (es) 2014-01-10
US8658649B2 (en) 2014-02-25
WO2008033798A3 (en) 2008-05-15
WO2008033798A2 (en) 2008-03-20
TN2009000049A1 (en) 2010-08-19
CO6160236A2 (es) 2010-05-20
AU2007296592A1 (en) 2008-03-20
GT200900055A (es) 2010-07-28
CN101511838A (zh) 2009-08-19
UA94622C2 (en) 2011-05-25
US20100035884A1 (en) 2010-02-11
TN2009000050A1 (en) 2010-08-19
CA2663175A1 (en) 2008-03-20
PT2094708E (pt) 2014-01-07
RU2440352C2 (ru) 2012-01-20
AU2007296592B2 (en) 2011-12-15
RU2009113615A (ru) 2010-10-20
EP2094708B1 (en) 2013-10-23
UY30584A1 (es) 2008-05-02
IL197381A0 (en) 2009-12-24
US20140142110A1 (en) 2014-05-22
MY148107A (en) 2013-02-28
CA2663175C (en) 2012-03-13
JP5161237B2 (ja) 2013-03-13
IL197381A (en) 2013-11-28
CL2007002617A1 (es) 2008-05-16
CR10636A (es) 2009-03-20
TWI399379B (zh) 2013-06-21
ZA200901073B (en) 2009-12-30
CN103804383A (zh) 2014-05-21
DK2094708T3 (da) 2014-01-27
PE20081372A1 (es) 2008-11-27

Similar Documents

Publication Publication Date Title
NO20091265L (no) Pyrrolopyrazin som Syk-kinase inhibitor
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
NO20083717L (no) Pyrrolotriazin-anilin prodrugforbindelser anvendbare som kinaseinhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
MX2009011579A (es) Pirimidinonas como moduladores de caseina cinasa ii (ck2).
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
SE0400284D0 (sv) Novel compounds
WO2009155121A3 (en) Inhibitors of pi3 kinase
NO20083267L (no) Azaindole inhibitorer av aurora kinaser
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
MX2010004263A (es) Inhibidores de quinasa c-fms.
NO20081454L (no) Met-kinaseinhibitorer
WO2009016460A8 (en) Pyrazole compounds and their use as raf inhibitors
UA94129C2 (ru) Соединения для ингибирования митоза
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
TNSN08191A1 (en) Kinase inhibitors
MX2009007302A (es) Derivados de purina.
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
NO20084202L (no) 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application